Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer

References

• Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-12; PMID:18772396; https://doi.org/10.1126/science.1164382
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013; 19:764-72; PMID:23209033; https://doi.org/10.1158/1078-0432.CCR-12-3002
   PubMed Web of Science ®Google Scholar
• Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340:626-30; PMID:23558169; https://doi.org/10.1126/science.1236062
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Kohne CH. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48:1466-75; PMID:22446022; https://doi.org/10.1016/j.ejca.2012.02.057
   PubMed Web of Science ®Google Scholar
• Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370:2537-9; PMID:24963575; https://doi.org/10.1056/NEJMoa1311107
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371:1963-71; PMID:25264305; https://doi.org/10.1056/NEJMoa1406766
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-80; PMID:12181401; https://doi.org/10.1056/NEJMoa020461
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366:2171-9; PMID:22670903; https://doi.org/10.1056/NEJMoa1113713
   PubMed Web of Science ®Google Scholar
• Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010; 3:47; PMID:21108851; https://doi.org/10.1186/1756-8722-3-47
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30-9; PMID:25399551; https://doi.org/10.1056/NEJMoa1412690
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; https://doi.org/10.1056/NEJMoa1103782
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366:1382-92; PMID:22452356; https://doi.org/10.1056/NEJMoa1105535
   PubMed Web of Science ®Google Scholar
• Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14:461-71; PMID:23602601; https://doi.org/10.1016/S1470-2045(13)70130-X
   PubMed Web of Science ®Google Scholar
• Sherrill B, Amonkar MM, Sherif B, Maltzman J, O'Rourke L, Johnston S. Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist 2010; 15:944-53; PMID:20798196; https://doi.org/10.1634/theoncologist.2010-0012
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005; 353:1734-6; PMID:16236745; https://doi.org/10.1056/NEJMe058196
   PubMed Web of Science ®Google Scholar
• Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011; 364:947-55; PMID:21388312; https://doi.org/10.1056/NEJMct0807960
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. Silver Spring, MD: US. Food and Drug Administration, 2016.
   Google Scholar
• Mullard A. Pioneering apoptosis-targeted cancer drug poised for FDA approval. Nat Rev Drug Discov 2016; 15:147-9; PMID:26931080; https://doi.org/10.1038/nrd.2016.23
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim Biophys Acta 2014; 1846:326-41; PMID:24880135; https://doi.org/10.1016/j.bbcan.2014.05.004
   PubMed Web of Science ®Google Scholar
• Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491:399-405; PMID:23103869; https://doi.org/10.1038/nature11547
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-6; PMID:18772397; https://doi.org/10.1126/science.1164368
   PubMed Web of Science ®Google Scholar
• Margittai E, Banhegyi G. Isocitrate dehydrogenase: A NADPH-generating enzyme in the lumen of the endoplasmic reticulum. Arch Biochem Biophys 2008; 471:184-90; PMID:18201546; https://doi.org/10.1016/j.abb.2007.12.017
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-73; PMID:19228619; https://doi.org/10.1056/NEJMoa0808710
   PubMed Web of Science ®Google Scholar
• Gupta R, Flanagan S, Li CC, Lee M, Shivalingham B, Maleki S, Wheeler HR, Buckland ME. Expanding the spectrum of IDH1 mutations in gliomas. Mod Pathol 2013; 26:619-25; PMID:23307057; https://doi.org/10.1038/modpathol.2012.210
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462:739-44; PMID:19935646; https://doi.org/10.1038/nature08617
   PubMed Web of Science ®Google Scholar
• Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012; 483:484-8; PMID:22343896; https://doi.org/10.1038/nature10898
   PubMed Web of Science ®Google Scholar
• Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL, Kaelin WG, Jr. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339:1621-5; PMID:23393090; https://doi.org/10.1126/science.1231677
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483:474-8; PMID:22343901; https://doi.org/10.1038/nature10860
   PubMed Web of Science ®Google Scholar
• Leonardi R, Subramanian C, Jackowski S, Rock CO. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J Biol Chem 2012; 287:14615-20; PMID:22442146; https://doi.org/10.1074/jbc.C112.353946
   PubMed Web of Science ®Google Scholar
• Wang JB, Dong DF, Wang MD, Gao K. IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo. Asian Pac J Cancer Prev 2014; 15:427-32; PMID:24528069; https://doi.org/10.7314/APJCP.2014.15.1.427
   PubMedGoogle Scholar
• Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res 2012; 18:4266-76; PMID:22896693; https://doi.org/10.1158/1078-0432.CCR-11-3114
   PubMed Web of Science ®Google Scholar
• Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015; 129:829-48; PMID:25943888; https://doi.org/10.1007/s00401-015-1432-1
   PubMed Web of Science ®Google Scholar
• Yan H, Bigner DD, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 2009; 69:9157-9; PMID:19996293; https://doi.org/10.1158/0008-5472.CAN-09-2650
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-25; PMID:21561347; https://doi.org/10.1056/NEJMoa1011923
   PubMed Web of Science ®Google Scholar
• Western Regional Medical Center. A Phase Ib/II study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Clinicaltrials.gov [ NCT02331251]. Bethesda, MD: National Library of Medicine (US), 2015.
   Google Scholar
• Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DTW. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathologica 2015; 129:133-46; PMID:25427834; https://doi.org/10.1007/s00401-014-1370-3
   PubMed Web of Science ®Google Scholar
• Agios Pharmaceuticals Inc. A phase 1, multicenter, open-label, dose-escalation and expansion, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-120 in subjects with advanced solid tumors, including glioma, with an IDH1 mutation. ClinicalTrialsgov [ Internet]. Bethesda, MD: National Library of Medicine (US), 2015.
   Google Scholar
• Amato E, Molin MD, Mafficini A, Yu J, Malleo G, Rusev B, Fassan M, Antonello D, Sadakari Y, Castelli P, et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 2014; 233:217-27; PMID:24604757; https://doi.org/10.1002/path.4344
   PubMed Web of Science ®Google Scholar
• Winter JM, Ting AH, Vilardell F, Gallmeier E, Baylin SB, Hruban RH, Kern SE, Iacobuzio-Donahue CA. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 2008; 14:412-8; PMID:18223216; https://doi.org/10.1158/1078-0432.CCR-07-0487
   PubMed Web of Science ®Google Scholar
• Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget 2013; 4:1729-36; PMID:24077826; https://doi.org/10.18632/oncotarget.1412
   PubMed Web of Science ®Google Scholar
• Grassian AR, Lin F, Barrett R, Liu Y, Jiang W, Korpal M, Astley H, Gitterman D, Henley T, Howes R, et al. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). J Biol Chem 2012; 287:42180-94; PMID:23038259; https://doi.org/10.1074/jbc.M112.417832
   PubMed Web of Science ®Google Scholar